Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | LFS-1107, a reversible CRM1 inhibitor (Kd: 12.5 pM), selectively targets and eliminates ENKTL cells, offering potential for cancer research applications [1]. |
In vitro | LFS-1107 at concentrations of 4-9$ over 72 hours selectively eradicates ENKTL cells while preserving normal human PBMCs, demonstrating a favorable safety profile within the PBMC cell lineage [1]. |
In vivo | LFS-1107 (10 mg/kg, intraperitoneal injection, once weekly) can ameliorate the symptoms of ENKTL in a xenografted mouse model with SNK6 cells [1]. |
Molecular Weight | 305.38 |
Formula | C12H11N5OS2 |
Cas No. | 1799330-91-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.